Episode description
Episode description
Suicidal ideation and GLP-1 agonists, a repeat of PARADIGM HF in Chagas CM, CASTLE HTx critical appraisal, and primary prevention of SCD in HF are the topics John Mandrola, MD, covers this week.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
I. Suicidal ideation with GLP-1
Signal of Suicidality With GLP-1 RA Semaglutide, but Experts Urge Caution
- Disproportionality Analysis from World Health Organization Data on Semaglutide, Liraglutide, and Suicidality
- Variability in Disproportionality paper https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2021.668765/full
II. PARACHUTE HF: Repeating the Mistakes in PARADIGM HF
- PARACHUTE HF https://www.jacc.org/doi/10.1016/j.jchf.2024.05.021
- SOLVD https://www.nejm.org/doi/full/10.1056/NEJM199108013250501
- CONSENSUS trial https://www.nejm.org/doi/full/10.1056/NEJM198706043162301
- Meta-analysis of Low vs High Dose ACE/ARB https://doi.org/10.1161/CIRCHEARTFAILURE.117.003956
- Meta-analysis of Sac/Val vs ARB/ACE Inhibitors https://link.springer.com/article/10.1007/s00228-024-03686-6
- PARADISE MI https://www.nejm.org/doi/full/10.1056/NEJMoa2104508
III. CASTLE HTx Critical Appraisal
- Critical Appraisal of CASTLE HTx https://doi.org/10.1016/j.jacc.2024.06.020
- CASTLE HTx https://www.nejm.org/doi/10.1056/NEJMoa2306037
- CASTLE AF https://www.nejm.org/doi/full/10.1056/NEJMoa1707855
IV. More Data Suggesting Modest Benefits of the Primary Prevention ICD
- First and Recurrent ICD Shocks: JICE Paper from Denmark https://link.springer.com/article/10.1007/s10840-024-01873-0
- HF trialists https://www.nejm.org/doi/full/10.1056/NEJMoa1609758
PROFID Trial https://profid-project.eu/ - DANISH https://www.nejm.org/doi/full/10.1056/NEJMoa1608029
- SCD-HeFT https://www.nejm.org/doi/full/10.1056/NEJMoa043399
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net